3
FDA-approved indications
25,000+
patients treated through July 2022
$535M
annual net revenues (2021)
$201M
annual R&D investments (2021)
4
phase 3 trials in new indications
events and presentations

Feb 23, 2023
Novocure Q4 2022 Earnings Conference Call
Jan 10, 2023
41st Annual J.P. Morgan Healthcare Conference
view all
latest filings
view all
reports
See our online annual reports and more.

2021
annual materials

2020
annual report and ESG report

mission, vision and values
mission
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.
vision
Patient-forward: aspiring to make a difference in cancer
learn morecontact us
investorinfo@novocure.com
610-723-7427
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.